Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4BP6
The NM_000368.5(TSC1):āc.973C>Gā(p.Gln325Glu) variant causes a missense change. The variant allele was found at a frequency of 0.000000684 in 1,461,866 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
TSC1 (HGNC:12362): (TSC complex subunit 1) This gene is a tumor suppressor gene that encodes the growth inhibitory protein hamartin. The encoded protein interacts with and stabilizes the GTPase activating protein tuberin. This hamartin-tuberin complex negatively regulates mammalian target of rapamycin complex 1 (mTORC1) signaling which is a major regulator of anabolic cell growth. This protein also functions as a co-chaperone for Hsp90 that inhibits its ATPase activity. This protein functions as a facilitator of Hsp90-mediated folding of kinase and non-kinase clients, including TSC2 and thereby preventing their ubiquitination and proteasomal degradation. Mutations in this gene have been associated with tuberous sclerosis and lymphangioleiomyomatosis. [provided by RefSeq, May 2022]
Verdict is Uncertain_significance. Variant got 0 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.34072262).
BP6
Variant 9-132911509-G-C is Benign according to our data. Variant chr9-132911509-G-C is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 1464062.We mark this variant Likely_benign, oryginal submissions are: {Benign=1, Uncertain_significance=1}.
Review Status: criteria provided, single submitter
Collection Method: clinical testing
The p.Q325E variant (also known as c.973C>G), located in coding exon 8 of the TSC1 gene, results from a C to G substitution at nucleotide position 973. The glutamine at codon 325 is replaced by glutamic acid, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. -
Tuberous sclerosis 1 Benign:1
May 26, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Benign
Review Status: criteria provided, single submitter
Gain of phosphorylation at T329 (P = 0.223);.;Gain of phosphorylation at T329 (P = 0.223);Gain of phosphorylation at T329 (P = 0.223);Gain of phosphorylation at T329 (P = 0.223);Gain of phosphorylation at T329 (P = 0.223);Gain of phosphorylation at T329 (P = 0.223);Gain of phosphorylation at T329 (P = 0.223);Gain of phosphorylation at T329 (P = 0.223);.;.;Gain of phosphorylation at T329 (P = 0.223);Gain of phosphorylation at T329 (P = 0.223);Gain of phosphorylation at T329 (P = 0.223);Gain of phosphorylation at T329 (P = 0.223);Gain of phosphorylation at T329 (P = 0.223);.;Gain of phosphorylation at T329 (P = 0.223);